Last reviewed · How we verify
tolterodine SR, overactive bladder
tolterodine SR, overactive bladder is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently FDA-approved.
Tolterodine SR is a small molecule medication used to treat overactive bladder, as well as other urinary incontinence conditions such as mixed urinary incontinence and stress urinary incontinence. It is available under various brand names, including DETROL and DETROL LA.
At a glance
| Generic name | tolterodine SR, overactive bladder |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- A Study of YM178 in Subjects With Symptoms of Overactive Bladder (PHASE3)
- Pharmacological vs Surgical Treatment for Mixed Incontinence (PHASE4)
- Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB (PHASE4)
- Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) (PHASE4)
- Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome. (NA)
- Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tolterodine SR, overactive bladder CI brief — competitive landscape report
- tolterodine SR, overactive bladder updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI
Frequently asked questions about tolterodine SR, overactive bladder
What is tolterodine SR, overactive bladder?
Who makes tolterodine SR, overactive bladder?
What development phase is tolterodine SR, overactive bladder in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing